Nick Goulden

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 483 citations · Full text

Medicine, Hematology, Oncology +16

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pediatrics +13

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003

David O’Connor, Jessica Bate, Rachel Wade et al. · Blood · 2014 · 251 citations

Medicine, Infectious Diseases, Pediatrics +16

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

Inge M. van der Sluis, Lynda M. Vrooman, Rob Pieters et al. · Haematologica · 2016 · 239 citations · Full text

Life Sciences, Immunology, Oncology +11

Outcome for children and young people with <scp>E</scp>arly <scp>T</scp>‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, <scp>UKALL</scp> 2003

Katharine Patrick, Rachel Wade, Nick Goulden et al. · British Journal of Haematology · 2014 · 230 citations

Medicine, Oncology, Pediatrics +10